The Green Organic Dutchman (TSX:TGOD) Loses Considerable Value After Q3 Results Disappoint

The Green Organic Dutchman stock continues to spiral downwards in November 2019.

Powder of Cannabis (Drugs), Analysis of Cannabis in laboratory.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s premium investing services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn moresdf

Shares of cannabis company The Green Organic Dutchman (TSX:TGOD) are trading significantly lower today. The company announced its third-quarter results on November 14 after the market close.

It reported net revenue of $2.525 million, a year-over-year rise of 34.3% compared to sales of $1.88 million in the prior-year quarter. Its earnings per share fell to -$0.07 in the September quarter compared to -$0.04 in the prior-year period.

Analysts estimated the firm to post sales of $9.58 million with EPS of -$0.04 in the third quarter of 2019. As TGOD failed to meet consensus estimates on sales as well as earnings, the stock is trading lower by 8.5% in early market trading today.

The company continues to remain unprofitable. In Q3 TGOD’s gross profit stood at 62.6%. However, its sales and marketing expenses totaled $3.34 million, which were 132% of total sales. Further, general and administrative expenses stood at a mammoth $13.33 million in the September quarter, up from $5.68 million in the prior-year period.

This meant TGOD’s operating loss stood at $20.1 million, of which $4.3 million was related to non-cash stock-based compensation, depreciation, and amortization.

What were the key highlights for TGOD?

While the company missed consensus estimates in Q3, TGOD continues to focus on reducing losses going forward. Last month, it unveiled a new construction and operating plan for the Valleyfield manufacturing facility.

TGOD aims to demarcate the construction in its Valleyfield facility into smaller phases. It also invested $104 million in capital expenditures in the last quarter for construction at Ancaster and Valleyfield. TGOD received approval from Health Canada to expand operations in the Ancaster facility.

As part of TGOD’s strategic plan, the company aims to reduce operating losses by at least $3 million per quarter in 2020. This will mean the company will be able to post a positive operating cash flow by the end of the second quarter of 2020.

TGOD has entered the recreational cannabis market with a pilot test on Ontario that resulted in sales of $600,000 in Q3. It will continue to scale production to target the recreational market as well as prepare for the launch of Cannabis 2.0 later this year, as regulatory approvals for cannabis extracts topicals and vapes are in place.

The company CEO Brian Athaide stated, “Q3 marked TGOD’s entry into the recreational cannabis market with a small pilot in Ontario. We were thrilled to witness such positive feedback on product quality and packaging from retailers and consumers across the province. Based on the initial response, demand for high-quality flower is strong and TGOD is well positioned to capture the premium organic segment which is significantly underserved.”

TGOD is currently trading 86% below the 52-week high

We have seen the cannabis sector has been decimated since October 2018 in terms of market returns. TGOD is no exception. The stock has lost close to 90% in market value in the last few months.

As cannabis is a highly regulated industry, the retail store openings are taking longer than expected. This has resulted in lower-than-expected demand and higher inventory levels for TGOD and peers. At the end of September, TGOD’s inventory was valued at $5.81 million — a rise of 48% year over year.

The cannabis industry is in a nascent stage, making it difficult for companies to raise debt capital. TGOD stock fell over 50% in October 2019 after it failed to raise the required debt funding.

However, yesterday the firm announced it signed an agreement to raise up to $103 million in debt. These proceeds will be used for the completion of its Ancaster and Valleyfield facilities. While cannabis companies continue to expand manufacturing facilities, they still have to contend with a slow rollout of retail stores and competition from the illegal market.

This has led to high inventory levels and lower-than-expected sales. TGOD stock fell 9% yesterday as well after Canopy Growth reported earnings below estimates dragging several stocks lower.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Aditya Raghunath has no position in any of the stocks mentioned.  

More on Cannabis Stocks

Cannabis smoke
Cannabis Stocks

Canopy Growth Stock: Is Now a Good Time to Invest?

The road ahead is highly uncertain for Canopy Growth, as the stock is plagued with losses and seemingly unsurmountable industry…

Read more »

Cannabis grows at a commercial farm.
Cannabis Stocks

TLRY Stock: Should You Invest Now?

TLRY is a Canadian cannabis stock which is trading 91% below record highs. Let's see if you should own TLRY…

Read more »

Cannabis grows at a commercial farm.
Cannabis Stocks

Is Tilray Stock a Buy in February 2023?

Despite the volatile cannabis sector, Tilray could be a superb buy for long-term investors.

Read more »

Young woman sat at laptop by a window
Cannabis Stocks

Is SNDL Stock a Buy in February 2023?

SNDL is a beaten-down cannabis stock. While its revenue growth is exceptional, a weak balance sheet has driven stock prices…

Read more »

A cannabis plant grows.
Cannabis Stocks

TLRY Stock: Here’s What’s Coming in 2023

Tilray Inc. (TSX:TLRY) is geared up for big growth this decade and looks like one of the top cannabis stocks…

Read more »

A person holds a small glass jar of marijuana.
Cannabis Stocks

Canopy Growth Stock: Here’s What’s Coming in 2023

Canopy Growth stock has made a lot of new moves in the last few months, but where is the company…

Read more »

A cannabis plant grows.
Cannabis Stocks

Better Cannabis Buy: Canopy Growth Stock or Tilray?

Only two TSX weed stocks can deliver substantial returns in the highly anticipated growth of the global cannabis market.

Read more »

Medicinal research is conducted on cannabis.
Cannabis Stocks

Is Tilray Stock a Buy in January 2023?

Tilray stock has lost 50% of its value in the last 12 months, in line with its peers.

Read more »